VERV
Verve Therapeutics, Inc. [VERV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VERV Stock Summary
Top 10 Correlated ETFs
VERV
Top 10 Correlated Stocks
VERV
In the News
Verve Therapeutics: VERVE-101 On Hold, But Technology Remains Sound
Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular diseases. The company's research focuses on two genes, PCSK9 and ANGPTL3 - the lead product candidate, VERVE-101, aims to treat Heterozygous Familial Hypercholesterolemia (HeFH).
Verve Therapeutics: Opportunity For Quick Profit On Eventual Lifting Of Clinical Hold
Verve Therapeutics has been stuck with a clinical hold. There is no good reason the hold will not be lifted, say within a year or less.
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves.
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
The FDA has a bevy of safety concerns surrounding Verve's gene-editing approach to high cholesterol, leading VERV stock to dive Monday. The post Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns appeared first on Investor's Business Daily.
Verve Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in fireside chats during the following upcoming investor conferences:
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
A trial for the company's lead therapy was put on hold.
Why Is Verve Therapeutics (VERV) Stock Down 28% Today?
Verve Therapeutics (NASDAQ: VERV ) stock is taking a beating on Monday following bad news from the FDA. The unfortunate news for VERV shareholders is the FDA putting the company's VERVE-101 Investigational New Drug Application (IND) on hold.
Verve Crashes After FDA Halts Plan To Test Gene Editor In People
U.S. officials halted Verve's plan to begin testing in people a gene-editing approach to high cholesterol, leading VERV stock to crash. The post Verve Crashes After FDA Halts Plan To Test Gene Editor In People appeared first on Investor's Business Daily.
Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates
Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VERV Financial details
VERV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0.11 | |
| Net income per share | -0.66 | -2.58 | -6.78 | -8.87 | |
| Operating cash flow per share | -0.26 | -1.99 | -4.39 | -6.9 | |
| Free cash flow per share | -0.32 | -2.18 | -4.64 | -7.64 | |
| Cash per share | 0.64 | 4.07 | 20.32 | 31.28 | |
| Book value per share | -0.67 | -3.6 | 20.14 | 31.06 | |
| Tangible book value per share | -0.67 | -3.6 | 20.14 | 31.06 | |
| Share holders equity per share | -0.67 | -3.6 | 20.14 | 31.06 | |
| Interest debt per share | 0 | 0 | 0.11 | 4.62 | |
| Market cap | 931.22M | 566.24M | 654.05M | 343.26M | |
| Enterprise value | 928.23M | 557.25M | 591.68M | 309.77M | |
| P/E ratio | -48.26 | -12.39 | -5.44 | -2.18 | |
| Price to sales ratio | 0 | 0 | 0 | 176.85 | |
| POCF ratio | -125.13 | -16.06 | -8.4 | -2.81 | |
| PFCF ratio | -100.14 | -14.64 | -7.95 | -2.53 | |
| P/B Ratio | -47.63 | -8.86 | 1.83 | 0.62 | |
| PTB ratio | -47.63 | -8.86 | 1.83 | 0.62 | |
| EV to sales | 0 | 0 | 0 | 159.59 | |
| Enterprise value over EBITDA | -48.37 | -12.56 | -4.98 | -1.99 | |
| EV to operating cash flow | -124.73 | -15.8 | -7.6 | -2.53 | |
| EV to free cash flow | -99.82 | -14.4 | -7.19 | -2.29 | |
| Earnings yield | -0.02 | -0.08 | -0.18 | -0.46 | |
| Free cash flow yield | -0.01 | -0.07 | -0.13 | -0.39 | |
| Debt to equity | -2.11 | -2.23 | 0.07 | 0.23 | |
| Debt to assets | 1.9 | 1.82 | 0.07 | 0.19 | |
| Net debt to EBITDA | 0.16 | 0.2 | 0.53 | 0.22 | |
| Current ratio | 5.36 | 10.11 | 16.67 | 16.05 | |
| Interest coverage | 0 | 0 | 0 | 0 | |
| Income quality | 0.39 | 0.77 | 0.65 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 19.34 | |
| Research and developement to revenue | 0 | 0 | 0 | 67.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.25 | 0.1 | 0.06 | 0.11 | |
| Capex to revenue | 0 | 0 | 0 | -6.82 | |
| Capex to depreciation | -17.52 | -2.58 | -2.84 | -7.45 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 11.58 | |
| Graham number | 3.16 | 14.45 | 55.44 | 78.74 | |
| ROIC | -1.03 | -0.67 | -0.35 | -0.37 | |
| Return on tangible assets | -0.89 | -0.58 | -0.31 | -0.23 | |
| Graham Net | -0.77 | -3.96 | 18.81 | 24.04 | |
| Working capital | 15.5M | 66.65M | 345.1M | 528.06M | |
| Tangible asset value | -19.55M | -63.91M | 357.35M | 550.93M | |
| Net current asset value | -22.15M | -68.36M | 340.36M | 434.87M | |
| Invested capital | 0 | 0 | 0.01 | 0.15 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 1.22M | 3.56M | 4.75M | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | 0.99 | 0.72 | -0.34 | -0.29 | |
| Capex per share | -0.06 | -0.19 | -0.25 | -0.75 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0.02 | 0.06 | |
| Net income per share | -0.65 | -0.62 | -0.84 | -0.79 | -2.32 | |
| Operating cash flow per share | -0.58 | -0.69 | -0.55 | -0.51 | -1.85 | |
| Free cash flow per share | -0.6 | -0.75 | -0.61 | -0.56 | -2.13 | |
| Cash per share | 7.51 | 6.66 | 6.03 | 9.63 | 31.28 | |
| Book value per share | 7.44 | 6.82 | 6.09 | 9.58 | 31.06 | |
| Tangible book value per share | 7.44 | 6.82 | 6.09 | 9.58 | 31.06 | |
| Share holders equity per share | 7.44 | 6.82 | 6.09 | 9.58 | 31.06 | |
| Interest debt per share | 0.04 | 0.03 | 0.02 | 1.43 | 4.62 | |
| Market cap | 1.77B | 1.11B | 743.75M | 1.97B | 343.26M | |
| Enterprise value | 1.71B | 1.02B | 671.77M | 1.77B | 309.77M | |
| P/E ratio | -14.13 | -9.19 | -4.54 | -10.87 | -2.09 | |
| Price to sales ratio | 0 | 0 | 0 | 2.12K | 339.19 | |
| POCF ratio | -63.14 | -33.08 | -27.8 | -67.35 | -10.44 | |
| PFCF ratio | -61.01 | -30.44 | -25.23 | -61.77 | -9.07 | |
| P/B Ratio | 4.96 | 3.34 | 2.51 | 3.59 | 0.62 | |
| PTB ratio | 4.96 | 3.34 | 2.51 | 3.59 | 0.62 | |
| EV to sales | 0 | 0 | 0 | 1.9K | 306.09 | |
| Enterprise value over EBITDA | -55.35 | -34.44 | -16.8 | -41.6 | -7.53 | |
| EV to operating cash flow | -60.92 | -30.39 | -25.11 | -60.6 | -9.42 | |
| EV to free cash flow | -58.86 | -27.97 | -22.79 | -55.58 | -8.18 | |
| Earnings yield | -0.02 | -0.03 | -0.06 | -0.02 | -0.12 | |
| Free cash flow yield | -0.02 | -0.03 | -0.04 | -0.02 | -0.11 | |
| Debt to equity | 0.07 | 0.05 | 0.09 | 0.23 | 0.23 | |
| Debt to assets | 0.07 | 0.05 | 0.09 | 0.19 | 0.19 | |
| Net debt to EBITDA | 2.02 | 3.04 | 1.8 | 4.64 | 0.81 | |
| Current ratio | 16.67 | 22.21 | 11.55 | 19.35 | 16.05 | |
| Interest coverage | 0 | -389.33 | -136.99 | -22.2 | 0 | |
| Income quality | 0.89 | 1.11 | 0.65 | 0.65 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 10.33 | 11.3 | |
| Research and developement to revenue | 0 | 0 | 0 | 37.89 | 36.84 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.09 | 0.1 | 0.09 | 0.15 | |
| Capex to revenue | 0 | 0 | 0 | -2.84 | -4.91 | |
| Capex to depreciation | -2.08 | -5.66 | -4.2 | -3.68 | 48.71 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 6.37 | 6.62 | |
| Graham number | 10.45 | 9.76 | 10.73 | 13.05 | 40.23 | |
| ROIC | -0.13 | -0.19 | -0.25 | -0.37 | -0.11 | |
| Return on tangible assets | -0.08 | -0.09 | -0.13 | -0.07 | -0.06 | |
| Graham Net | 6.95 | 6.29 | 5.46 | 7.45 | 24.04 | |
| Working capital | 345.1M | 314.03M | 272.8M | 532.61M | 528.06M | |
| Tangible asset value | 357.35M | 331.39M | 296.33M | 547.94M | 550.93M | |
| Net current asset value | 340.36M | 310.98M | 270.71M | 436.22M | 434.87M | |
| Invested capital | 0.01 | 0 | 0 | 0.15 | 0.15 | |
| Average receivables | 0 | 0 | 0 | 464.5K | 464.5K | |
| Average payables | 5.33M | 4.76M | 4.38M | 3.39M | 1.44M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 90 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 1 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.09 | -0.09 | -0.14 | -0.08 | -0.07 | |
| Capex per share | -0.02 | -0.06 | -0.06 | -0.05 | -0.28 |
VERV Frequently Asked Questions
What is Verve Therapeutics, Inc. stock symbol ?
Verve Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VERV
Is Verve Therapeutics, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $13. The lowest prediction is $13 and the highest is $13
What is VERV stock prediction ?
What is Verve Therapeutics, Inc. stock quote today ?
Verve Therapeutics, Inc. stock price is $14.42 today.
Is Verve Therapeutics, Inc. stock public?
Yes, Verve Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 701.97K
- Market Capitalization 891.64M
- Employee 113
- CEO Dr. Sekar Kathiresan M.D.
- Headquarters Cambridge,MA,US
- IPO Date 2021-06-17
-
Website
https://www.vervetx.com 
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
